Breaking News, Collaborations & Alliances

Neurophet, AriBio Partner to Develop a Next-Gen Platform for Alzheimer’s Diagnosis

Aim to reduce unnecessary amyloid-PET scans and actively utilize a more accessible Alzheimer's disease testing method.

Author Image

By: Charlie Sternberg

Associate Editor

Neurophet, an artificial intelligence (AI) solution company for brain disease, has joined forces with AriBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, to develop a next-generation platform for Alzheimer’s diagnosis.   The collaboration seeks to create a novel diagnostic platform for Alzheimer’s by combining Neurophet’s MRI-based brain image analysis technology with fluid biomarker data obtained from AriBio’s global Phase 3 clinica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters